The AASK Cohort Study

AASK 队列研究

• 批准号: 6937099
• 负责人: WILLIAM H CLEVELAND
• 金额: $ 2.89万
• 依托单位: MOREHOUSE SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-29 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6937099
• 关键词: ACE inhibitors; African American; antihypertensive agents; blood chemistry; blood pressure; cardiovascular disorder; cardiovascular disorder chemotherapy; chronic renal failure; clinical research; comorbidity; cooperative study; creatinine; data collection methodology /evaluation; disease /disorder proneness /risk; echocardiography; human subject; human therapy evaluation; kidney function; outcomes research; patient oriented research; questionnaires; renal hypertension; sample collection

DESCRIPTION (provided by applicant): Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.

描述（由申请人提供）： 高血压肾病通常会进展。 AASK（非裔美国人肾脏疾病和高血压研究）队列研究的主要目标是前瞻性地确定接受推荐抗高血压治疗的患有高血压肾病的非裔美国人的肾功能过程和肾脏疾病进展的危险因素。次要目标是确定心血管疾病的发生并评估其危险因素。 AASK 队列研究是一项前瞻性观察性研究，是 AASK 试验的延伸。 AASK 试验测试了 3 种用作初始抗高血压治疗的药物（雷米普利、美托洛尔和氨氯地平）和 2 种血压控制水平的效果。在 1,094 名试验参与者中，大约 650 至 700 名未达到终末期肾病 (ESRD) 的个体可能会参加队列研究。要研究的风险因素包括环境、遗传、生理和社会经济变量。主要肾脏结局是一种复合临床结局，定义为血清肌酐加倍、ESRD 或死亡。向所有参与者提供高血压药物治疗，从血管紧张素转换酶抑制剂雷米普利开始。通过这种方式，该研究直接控制了肾脏疾病进展的两个主要决定因素（高血压的治疗和肾保护性抗高血压药物的使用）。队列研究的最短随访时间为 5 年（总计 9 至 12 年，包括 AASK 试验期间）。 最终，AASK 队列研究的数据应该会增强我们对决定肾脏疾病进展的危险因素和过程的理解。这些结果可能最终会导致延迟或预防 ESRD 的新策略。